Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
donor lymphocyte infusion (Chinese PLA General Hospital)
- Development stage
- Unknown
- Lead developer
- Chinese PLA General Hospital
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Donor lymphocyte infusion (DLI) is an adoptive cellular immunotherapy used to prevent or treat relapse in patients following allogeneic hematopoietic stem cell transplantation (allo-HSCT). The therapy involves the administration of lymphocytes from the original donor to the recipient to harness the graft-versus-leukemia (GVL) effect, where donor T cells identify and destroy residual malignant cells. The Chinese PLA General Hospital has specifically evaluated prophylactic G-CSF-primed DLI (GP-DLI) in patients with high-risk hematologic malignancies, such as leukemia and lymphoma. This protocol may include the use of decitabine as a conditioning or synergistic agent for patients with specific high-risk genetic mutations (e.g., TP53, TET2, DNMT3a) to enhance the anti-tumor efficacy of the infused lymphocytes.
- Other names
- DLIDonor lymphocyte infusionProphylactic donor lymphocyte infusionG-CSF-primed donor lymphocyte infusion
02
Targets
pMHC-II (Peptide-major histocompatibility complex class II complex)MHC I (MHC class I})TCR (T cell antigen receptor complex)
Beyond the preview
Go deeper on donor lymphocyte infusion (Chinese PLA General Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on donor lymphocyte infusion (Chinese PLA General Hospital).